Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease

• Published in: Intestinal research Vol. 18; no. 4; pp. 355 - 378
• Main Authors: Sood, Ajit, Ahuja, Vineet, Midha, Vandana, Sinha, Saroj Kant, Pai, C. Ganesh, Kedia, Saurabh, Mehta, Varun, Bopanna, Sawan, Abraham, Philip, Banerjee, Rupa, Bhatia, Shobna, Chakravartty, Karmabir, Dadhich, Sunil, Desai, Devendra, Dwivedi, Manisha, Goswami, Bhabhadev, Kaur, Kirandeep, Khosla, Rajeev, Kumar, Ajay, Mahajan, Ramit, Misra, S. P., Peddi, Kiran, Singh, Shivaram Prasad, Singh, Arshdeep
• Format: Journal Article
• Language: English
• Published: Korean Association for the Study of Intestinal Diseases 01.10.2020; 대한장연구학회
• Subjects: 5-aminosalicylic acid; colitis, ulcerative; crohn disease; inflammatory bowel disease; mesalamine; Review; 내과학
• ISSN: 1598-9100; 2288-1956
• DOI: 10.5217/ir.2019.09176

Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD.